摘要
为探讨全身骨显像有多处异常放射性药物浓聚的患者血清肿瘤标志物含量及结果分析。对73例恶性肿瘤患者分为病灶组36例和疾病对照组37例,行全身骨显像和血清五项肿瘤标志物检测,对37名无肿瘤病史的体检健康人为正常组,行血清五项肿瘤标志物检测。分别对病灶组和疾病对照组以及病灶组与正常组进行肿瘤标志物AFP、CEA、CA125、CA15-3和CA19-9的检测数据进行统计和分析。结果表明36例全身骨显像有多发异常放射性浓聚病灶的病灶组与37例无异常骨显像的疾病对照组比较,两组中仅CEA含量有显著性差异(P<0.005),其余四项肿瘤标志物无显著性差异(P>0.05)。病灶组与正常组比较,CEA、CA125和CA19-9三项的结果存在显著性差异(P<0.005)。在临床实践中全身骨显像与血清肿瘤标志物检查有机结合,对肿瘤骨转移的诊断有一定的临床意义。
To study the serum tumor markers in patients with multiple abnormal concentration of radiopharmaceuticals in whole body bone imagine, 73 patients with malignancy were under a whole body bone scan. The serum tumor markers levels of AFP, CEA, CA125,CA15-3 and CA19-9 were measured in 73 patients and 37 normal people. The results showed that there was significant difference only on serum CEA level （P〈0. 005）, and no significant difference on CA125, CA15-3 and CA19-9 levels （P〈0.05） between 36 patients with multiple abnormal concentration and the others with normal bone imagine. The serum levels of CEA, CA125 and CA19-9 in patients were significant higher than that of normal controls （P〈0. 005）. Combined the whole body bone scan and detection of serum tumor markers might be regarded as clinical significance for the diagnosis of bone metastases.
出处
《标记免疫分析与临床》
CAS
2008年第2期68-70,共3页
Labeled Immunoassays and Clinical Medicine
